View Older Stories View More Recent Stories
-
Roth Reinstates BioLineRx (BLRX) at 'Buy'; Strong Pipeline Reinforces Upside Potential
-
Roth Capital Resumes BioLineRx (BLRX) at Buy
-
Medigus Announces Signing of $11.1 Million Private Placement by Leading Israeli and U.S. Institutions
-
Roth Capital Remains Positive on Stemline (STML); Management Updates on SL-401, SL-701
-
IGI Labs (IG) Prices 4.65M Common Offering at $5 Apiece
-
Roth Capital Starts Dot Hill (HILL) at Buy
-
IGI Laboratories (IG) Annouces Stock Offering
-
Slow Ramp Leaves R-22 Pricing Flat; Roth Keeps Hudson Tech (HDSN) at 'Buy'
-
Roth Capital Keeps LIgand Pharma (LGND) at Buy; Glaxo Initiates Promacta Phase III
-
Wunderlich Expands into Consumer and Business Services Investment Banking
-
Roth Capital Starts Concur Technologies (CNQR) at Buy
-
Roth 'Encouraged' by TG Therapeutics (TGTX), Ligand (LGND) Deal; Issues Commentary
-
Roth Affirms Hydrogenics (HYGS) at Buy; JV with Kolon Water is Step in Right Direction
-
Streetinsider.com's Hot Lunchtime Reads 06/23: (MSFT) (LGND) (RSH) (YELP)
-
Roth Capital Comments on New SERM Lasofoxifene Phase 1 Data
-
Unusual 11 Mid-Day Movers 06/20: (KMX) (FLML) (CARA) Higher; (MACK) (PVCT) (CLRX) Lower
-
SolarCity (SCTY) Continues Higher Following Silevo Deal, Management Commentary
-
Roth Capital Starts Prosensa (RNA) at Neutral
-
Roth Capital Starts Superior Drilling Products (SDPI) at Buy
-
Roth Boosts Target on SolarCity (SCTY) to $80; Silevo Acquisition 'Makes Sense'
-
Yingli Green Energy (YGE) Could See H214 Ramp; Roth Capital Keeps at 'Neutral'
-
Roth 'Impressed' at Early Completion of Enrollment in Galena's (GALE) GALE-301 Phase 2a; Keeps at 'Buy'
-
UPDATE: Short-Seller Article on Ligand (LGND) is Silly, Underlying Strength Remains - Roth Capital
-
LGD-6972 Could Drive Partnership; Roth Keeps Ligand Pharma (LGND) at 'Buy'
-
New Promacta Data Should Support Approval for cITP; Roth has Ligand (LGND) at 'Buy'
-
Roth 'Encouraged' by TG Therapeutics' (TGTX) TG-1101 Phase 2 Prelim Results; Boosts PT to $20
-
Notable Analyst Rating Changes 06/13: (INTC) (GEF) (NMBL) Upgraded; (MRVL) (LULU) (MRO) Downgraded
-
Pre-Open Stock Movers 6/13: (OPEN) (EXPR) (ICLD) Higher; (FNSR) (OCLS) (ETRM) Lower (more...)
-
Roth Capital Starts Conatus Pharmaceuticals (CNAT) at Buy
-
Roth Capital Upgrades Intel (INTC) to Buy
-
Roth Capital Starts Fusion-io (FIO) at Buy
-
Worst of Capstone Turbine (CPST) Probably Priced in; Roth Affirms 'Buy' Rating
-
Roth Comments on Regeneron (REGN), Sanofi Presentation of Sarilumab Phase 3 Data; Affirms at 'Buy'
-
Roth Comments on Regeneron's (REGN) MAA Submission for EYLEA to EU; Reaffirms 'Buy' Rating
-
Roth Positive on TG Therapeutics (TGTX) into EHA Presentation
-
Roth Affirms 'Buy' Rating on MEI Pharma (MEIP); New AML Treatment Data Bolsters Confidence
-
Roth Halves PT on Dendreon (DNDN) to 50c; Things Aren't Shaping Up Nicely
-
Roth Keeps Pharmacyclics (PCYC) at 'Buy'; Imbruvica sNDA Selected for Priority Review by FDA
-
Roth Capital Starts MacroGenics (MGNX) at Buy
-
Marrone Bio Innovations Announces Pricing of Follow-on Offering
-
Hudson Technologies, Inc. (HDSN) Plans Common Stock Offering
-
Culture Still Intact at Curis (CRIS) Following Management Shift; Roth Affirms at 'Buy'
-
LeMaitre Vascular, Inc. Closes Public Offering of Common Shares
-
Roth Comments on DoC Prelim. Countervailing Duties (SCTY) (SPWR) (FSLR) (YGE)
-
Pharmacyclics (PCYC) KOL Event at ASCO Impresses Physicians; Roth Keeps at 'Buy'
-
ORR in Sunesis Pharma's (SNSS) Vosaroxin + Decitabine Phase III Improves; Roth Affirms 'Buy' Rating
-
Synta (SNTA) Management Ready to Take Company to Next Level; Roth Affirms 'Buy' Rating
-
Roth Keeps Celldex (CLDX) at 'Focus Pick'; Strong Phase I Data for Varlilumab Only Adds to Story
-
Cytokinetics (CYTK) BENEFIT-ALS Update 'Encouraging'; Roth Maintains 'Buy' Rating
-
Roth Still Positive on Galena Biopharma (GALE) Following GALE-301 FBP Presentation; Issues Commentary

